ELAB
Elevai Labs, Inc. Common Stock
NASDAQ: ELAB · HEALTHCARE · BIOTECHNOLOGY
$1.88
-8.88% today
Updated 2026-06-05
Market cap
$7.00M
P/E ratio
—
P/S ratio
5.50x
EPS (TTM)
$-150.06
Dividend yield
—
52W range
$2 – $267
Volume
8.9M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F4.0
Quality
C2.5
Profitability
F5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-2.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -2.92 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-3.34M
- Revenue declining -45.80% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $766277.00 | $1.71M | $2.47M | $590084.00 | $1.27M |
| Net income | $-1.80M | $-4.30M | $-6.25M | $-7.71M | $-4.97M |
| EPS | — | — | — | — | $-150.06 |
| Free cash flow | $-1.62M | $-4.57M | $-5.50M | $-6.38M | $-3.34M |
| Profit margin | -234.94% | -251.17% | -253.14% | -1,306.28% | — |
Peer comparison
Smart narrative
Elevai Labs, Inc. Common Stock trades at $1.88. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -2.92, it sits in the distress. TTM revenue stands at $1.27M.
Frequently asked questions
What is Elevai Labs, Inc. Common Stock's stock price?
Elevai Labs, Inc. Common Stock (ELAB) trades at $1.88, on a P/S of 5.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Elevai Labs, Inc. Common Stock overvalued?
Elevai Labs, Inc. Common Stock carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is Elevai Labs, Inc. Common Stock's revenue?
Elevai Labs, Inc. Common Stock's trailing twelve-month revenue is $1.27M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Elevai Labs, Inc. Common Stock's Altman Z-Score is -2.92, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.50x
ROE-88.10%
Beta-0.28
50D MA$3.00
200D MA$63.79
Shares out0.00B
Float0.00B
Short ratio—
Avg volume8.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—